Leerink initiated coverage of SAB Biotherapeutics (SABS) with an Outperform rating and $7 price target SAB is a clinical-stage biotech focused on the development of lead asset SAB-142 – a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback